{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:42:01Z","timestamp":1782963721584,"version":"3.54.5"},"reference-count":48,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Liver Coalition and the San Diego Center for AIDS Research (SD CFAR), an NIH-funded program","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]},{"name":"The Liver Coalition and the San Diego Center for AIDS Research (SD CFAR), an NIH-funded program","award":["NU38FT000006"],"award-info":[{"award-number":["NU38FT000006"]}]},{"name":"The Liver Coalition and the San Diego Center for AIDS Research (SD CFAR), an NIH-funded program","award":["H24PC7790"],"award-info":[{"award-number":["H24PC7790"]}]},{"name":"CDC","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]},{"name":"CDC","award":["NU38FT000006"],"award-info":[{"award-number":["NU38FT000006"]}]},{"name":"CDC","award":["H24PC7790"],"award-info":[{"award-number":["H24PC7790"]}]},{"name":"California HIV\/AIDS Research Program","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]},{"name":"California HIV\/AIDS Research Program","award":["NU38FT000006"],"award-info":[{"award-number":["NU38FT000006"]}]},{"name":"California HIV\/AIDS Research Program","award":["H24PC7790"],"award-info":[{"award-number":["H24PC7790"]}]},{"name":"NIAID, NCI, NHLBI, NIA, NICHD, NIDA, NIDCR, NIDDK, NIMH, NIMHD, NINR, FIC, and OAR","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]},{"name":"NIAID, NCI, NHLBI, NIA, NICHD, NIDA, NIDCR, NIDDK, NIMH, NIMHD, NINR, FIC, and OAR","award":["NU38FT000006"],"award-info":[{"award-number":["NU38FT000006"]}]},{"name":"NIAID, NCI, NHLBI, NIA, NICHD, NIDA, NIDCR, NIDDK, NIMH, NIMHD, NINR, FIC, and OAR","award":["H24PC7790"],"award-info":[{"award-number":["H24PC7790"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In 2020, the Eliminate Hepatitis C Initiative in the county of San Diego (COSD) was launched, a private\u2013public joint endeavor between the COSD and the American Liver Foundation. We use epidemic modeling to assess whether the COSD is on track to reach its elimination targets (80% reduction in incidence, 65% reduction in hepatitis C virus (HCV)-related mortality by 2030 compared to 2015) and what intervention scale-up may be required. We adapted a previously developed dynamic, deterministic model of HCV transmission and disease progression among adults in the COSD, stratified by risk, age, gender, and human immunodeficiency virus (HIV) status. The model is calibrated to detailed historical epidemiological data on HCV burden, treatment, and mortality in the COSD. We project HCV infections and mortality under status quo HCV treatment (65%\/year among people coinfected with HCV and HIV, 0\u20135%\/year among others) and determine what treatment scale-up among those without HIV is required to achieve HCV elimination, with or without concomitant reductions in injection transmission risk from 2024 onward. We project an increase in new HCV infections in the COSD to 2213 [95% C.I.: 1069\u20133763] in 2030, a mean 91% relative increase between 2015 and 2030. HCV-related deaths are expected to decrease to 246 [95% C.I.: 180\u2013295] in 2030, a mean relative decrease of 14% compared to 2015. The incidence elimination target could be achieved through increasing HCV treatment among those without HIV to a mean of 60%\/year, similar to the level achieved among people coinfected with HCV and HIV. Combination interventions reduce the treatment needed; if injecting risk is reduced by 25%, then treating 48%\/year could achieve elimination. The COSD is likely not on track to reach the incidence or mortality targets, but achieving the incidence target is possible if treatment rates overall are scaled-up to rates that have been achieved among people coinfected with HCV and HIV. Elimination is achievable but requires committed funding and expansion of comprehensive testing, linkage, and treatment programs alongside harm reduction initiatives.<\/jats:p>","DOI":"10.3390\/v16121819","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:07:32Z","timestamp":1732277252000},"page":"1819","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention Strategies"],"prefix":"10.3390","volume":"16","author":[{"given":"Jaskaran S.","family":"Cheema","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Suckow","sequence":"additional","affiliation":[{"name":"The Liver Coalition, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ramers","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"Family Health Centers San Diego, San Diego, CA 92123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Loose","sequence":"additional","affiliation":[{"name":"County of San Diego Health and Human Services Agency, San Diego, CA 92123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tomada","sequence":"additional","affiliation":[{"name":"County of San Diego Health and Human Services Agency, San Diego, CA 92123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Tweeten","sequence":"additional","affiliation":[{"name":"County of San Diego Health and Human Services Agency, San Diego, CA 92123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Stamos-Buesig","sequence":"additional","affiliation":[{"name":"Harm Reduction Coalition San Diego, San Diego, CA 92101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Abramovitz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-7313","authenticated-orcid":false,"given":"William H.","family":"Eger","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffanie A.","family":"Strathdee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K.","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","unstructured":"World Health Organization (2021, May 22). Consolidated Strategic Information Guidelines for Viral Hepatitis: Planning and Tracking Progress Towards Elimination. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241515191."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.adh7975","article-title":"White House budget includes push to eliminate hepatitis C","volume":"379","author":"Leslie","year":"2023","journal-title":"Science"},{"key":"ref_4","unstructured":"Alcorn, T. (2024, June 20). Lags Behind Other Countries in Hepatitis-C Treatment. The New York Times. Updated 29 April 2024. Available online: https:\/\/www.nytimes.com\/2024\/04\/28\/health\/hepatitis-c.html."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wynn, A., Tweeten, S., McDonald, E., Wooten, W., Lucas, K., Cyr, C.L., Hernandez, M., Ramirez, F., VanWormer, C., and Suckow, S. (2021). The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251635"},{"key":"ref_6","unstructured":"Suckow, S., and Ramers, C. (2021, May 22). Eliminate Hepatitis C COSD Initiative. Live Well San Diego, Available online: https:\/\/www.sandiegocounty.gov\/content\/dam\/sdc\/hhsa\/programs\/bhs\/documents\/NOC\/bhab\/Eliminate%20Hepatitis%20C%20San%20Diego%20County%20Inititiative%20PPT_BHAB.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"ofad153","DOI":"10.1093\/ofid\/ofad153","article-title":"Hepatitis C Virus Micro-elimination Among People With HIV in San Diego: Are We on Track?","volume":"10","author":"Cheema","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_8","unstructured":"San Diego Health and Human Services Agency (2021, May 22). HIV\/AIDS Epidemiology Report\u20142016, Available online: https:\/\/www.sandiegocounty.gov\/content\/dam\/sdc\/hhsa\/programs\/phs\/documents\/EpiReport2017final.pdf."},{"key":"ref_9","unstructured":"U.S. Centers for Disease Control and Prevention (2021, January 05). NCHHSTP AtlasPlus. Updated 1 October 2021, Available online: https:\/\/gis.cdc.gov\/grasp\/nchhstpatlas\/charts.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1097\/QAD.0000000000001592","article-title":"Limited overlap between phylogenetic HIV and hepatitis C virus clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM","volume":"31","author":"Vanhommerig","year":"2017","journal-title":"AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/cid\/ciu447","article-title":"Vertical transmission of hepatitis C virus: Systematic review and meta-analysis","volume":"59","author":"Benova","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/apc.2009.0111","article-title":"Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: The Women\u2019s Interagency HIV Study (WIHS)","volume":"23","author":"Frederick","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e100267","DOI":"10.1016\/j.jmh.2024.100267","article-title":"Differences in characteristics and interactions with close contacts among PWID in the San Diego Border Region before and during the COVID-19 pandemic","volume":"10","author":"Marquez","year":"2024","journal-title":"J. Migr. Health"},{"key":"ref_14","unstructured":"County of San Diego Health and Human Services Agency (2024, May 16). Opioid-Related Overdoses & Encounters in COSD, 2016\u20132020. Updated April 2023, Available online: https:\/\/www.sandiegocounty.gov\/content\/dam\/sdc\/hhsa\/programs\/phs\/CHS\/OD2A%202016-2020%20Retrospective%20Analysis.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1016\/S2214-109X(19)30483-8","article-title":"Interim effect evaluation of the hepatitis C elimination programme in Georgia: A modelling study","volume":"8","author":"Walker","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cld.915","article-title":"State of the Hepatitis C Virus Care Cascade","volume":"16","author":"Thomas","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Facente, S.N., Grebe, E., Burk, K., Morris, M.D., Murphy, E.L., Mirzazadeh, A., Smith, A.A., Sanchez, M.A., Evans, J.L., and Nishimura, A. (2018). Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200866"},{"key":"ref_19","unstructured":"Cachay, E.T.F., Hill, L., Ballard, C., Aquino, A., Qin, H., Jain, S., Martin, S., and Mathews, W.m.C. (2020, January 8\u201311). Progress and real-life challenges for HCV elimination in People living with HIV. Proceedings of the Conferences on Retrovirus and Opportunistic Infections, Boston, MA, USA."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tempalski, B., Pouget, E.R., Cleland, C.M., Brady, J.E., Cooper, H.L.F., Hall, H.I., Lansky, A., West, B.S., and Friedman, S.R. (2013). Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992\u20132007. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064789"},{"key":"ref_21","unstructured":"U.S. Centers for Disease Control and Prevention (2022, July 01). National Vital Statistics System, Mortality 1999\u20132020 on CDC WONDER Online Database, Available online: http:\/\/wonder.cdc.gov\/ucd-icd10.html."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cachay, E.R., Hill, L., Wyles, D., Colwell, B., Ballard, C., Torriani, F., and Mathews, W.C. (2014). The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102883"},{"key":"ref_23","unstructured":"(2024, July 12). FDAPermits Marketing of First Point-of-Care Hepatitis CRNATest, U.S. Food & Drug Administration. Updated 27 June 2024, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-first-point-care-hepatitis-c-rna-test."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/aje\/kwz097","article-title":"Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison","volume":"188","author":"Fraser","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"ref_26","unstructured":"Cheema, J.S., Flores Ortega, R., Reau, N., Bradley, H., Hall, E.W., Hoenigl, M., Strathdee, S.A., and Martin, N.K. (2024, January 8\u201311). Modeling Hepatitis C Virus Elimination in the United States: Are we on track to reach incidence targets?. Proceedings of the 12th International Conference on Health and Hepatitis in Substance Users, Athens, Greece."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciae372","article-title":"Illicit Fentanyl Use and Hepatitis C Virus Seroconversion Among People Who Inject Drugs in Tijuana and San Diego: Results From a Binational Cohort Study","volume":"79","author":"Friedman","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2468-1253(21)00311-3","article-title":"Methods indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by, WHO","volume":"7","author":"Artenie","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/liv.14352","article-title":"Hepatitis C elimination\u2014Macro-elimination","volume":"40","author":"Weiland","year":"2020","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jiac446","article-title":"HCV Microelimination for High-risk Special Populations","volume":"228","author":"Huang","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Blach, S., Razavi-Shearer, D., Mooneyhan, E., Estes, C., Razavi-Shearer, K., Gamkrelidze, I., and Razavi, H. (2022). Updated Evaluation of Global Progress Towards HBV and HCV Elimination, Preliminary Data Through 2021, American Association for the Study of Liver Diseases.","DOI":"10.1016\/S0168-8278(22)00834-0"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2036.2008.03657.x","article-title":"Effectiveness of pegylated interferon\/ribavirin combination in \u2018real world\u2019 patients with chronic hepatitis C virus infection","volume":"27","author":"Borroni","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1574887114666190306154650","article-title":"Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection","volume":"14","author":"Scotto","year":"2019","journal-title":"Rev. Recent Clin. Trials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: Results in real life","volume":"38","year":"2018","journal-title":"Liver Int."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Davies, A., Singh, K.P., Shubber, Z., Ducros, P., Mills, E.J., Cooke, G., and Ford, N. (2013). Treatment Outcomes of Treatment-Na\u00efve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055373"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2005","journal-title":"J. Viral Hepat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/gut.2010.217166","article-title":"Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men","volume":"60","author":"Thomson","year":"2010","journal-title":"Gut"},{"key":"ref_39","first-page":"1","article-title":"Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation","volume":"11","author":"Shepherd","year":"2007","journal-title":"Heal. Technol. Assess."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/ciac543","article-title":"Estimated Number of People Who Inject Drugs in the United States","volume":"76","author":"Bradley","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21149\/13980","article-title":"Cocirculaci\u00f3n y reemplazo de variantes de SARS-CoV-2 en espacios hacinados y poblaciones marginadas en la frontera M\u00e9xico-EUA","volume":"65","author":"Chaillon","year":"2022","journal-title":"Salud P\u00fablica M\u00e9xico"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Arias, E., and Xu, J.Q. (2022). United States Life Tables, 2019, National Center for Health Statistics. Number 19.","DOI":"10.15620\/cdc:132418"},{"key":"ref_44","unstructured":"(2021, May 21). Understanding the Current HIV Epidemic. Available online: https:\/\/aidsvu.org\/local-data\/united-states\/west\/california\/san-diego-county\/."},{"key":"ref_45","unstructured":"(2021, May 21). HIV Disease Among Adult\/Adolescent Males, San Diego County, 2017, Available online: https:\/\/www.sandiegocounty.gov\/content\/dam\/sdc\/hhsa\/programs\/phs\/documents\/Adult_Adol_Male_Through_12312017_final.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-7517-11-4","article-title":"Evaluating the impact of Mexico\u2019s drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: A binational mixed methods research agenda","volume":"11","author":"Robertson","year":"2014","journal-title":"Harm Reduct. J."},{"key":"ref_47","unstructured":"(2021, May 21). HIV Disease Among Females in San Diego County, 2017, Available online: https:\/\/www.sandiegocounty.gov\/content\/dam\/sdc\/hhsa\/programs\/phs\/documents\/Females_Through_12312017v04-11-19.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugpo.2017.06.006","article-title":"Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California","volume":"47","author":"Horyniak","year":"2017","journal-title":"Int. J. Drug Policy"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1819\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:37:53Z","timestamp":1760114273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["v16121819"],"URL":"https:\/\/doi.org\/10.3390\/v16121819","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}